APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Sexual Dysfunction

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drugs for Sexual Dysfunction Market Outlook and Growth Opportunities 2026

Report ID 173986490429 December 2025202 pages

Choose your research edition.

Industry ResearchDrugs for Sexual Dysfunction Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Sexual Dysfunction Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Drugs for Sexual Dysfunction Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Sexual Dysfunction Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Sexual Dysfunction Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Drugs for Sexual Dysfunction market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drugs for Sexual Dysfunction is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs for Sexual Dysfunction is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for Sexual Dysfunction is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drugs for Sexual Dysfunction market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drugs for Sexual Dysfunction market include Boston Scientific Corporation, CSBio, Dong-A ST, General Factory, Hims, Lilly ICOS LLC, Lupin, Meda Pharmaceuticals and Menarini Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Drugs for Sexual Dysfunction market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for Sexual Dysfunction and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Sexual Dysfunction sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs for Sexual Dysfunction market size, projected growth trends, production technologies, key applications, and end-use industries.

Drugs for Sexual Dysfunction Segment by Company

Boston Scientific Corporation

CSBio

Dong-A ST

General Factory

Hims

Lilly ICOS LLC

Lupin

Meda Pharmaceuticals

Menarini Group

Metuchen Pharma

SK Chemicals.

Vivus, Inc.

Bayer AG

Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.

Pfizer Inc

Lilly

Sanofi

Teva Pharmaceutical Industries Ltd.

Drugs for Sexual Dysfunction Segment by Type

Vardenafil (Levitra, Staxyn)

Tadalafil (Cialis)

Udenafil (Zydena)

Sildenafil (Viagra)

Others

Drugs for Sexual Dysfunction Segment by Application

Retail Pharmacies

Online Pharmacies

Hospitals

Clinics

Drugs for Sexual Dysfunction Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drugs for Sexual Dysfunction status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Drugs for Sexual Dysfunction market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs for Sexual Dysfunction significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs for Sexual Dysfunction competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Sexual Dysfunction market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Sexual Dysfunction and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Sexual Dysfunction.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Drugs for Sexual Dysfunction market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for Sexual Dysfunction industry.

Chapter 3: Detailed analysis of Drugs for Sexual Dysfunction manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Drugs for Sexual Dysfunction in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Drugs for Sexual Dysfunction in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs for Sexual Dysfunction Industry Trends Table 2. Drugs for Sexual Dysfunction Industry Drivers Table 3. Drugs for Sexual Dysfunction Industry Opportunities and Challenges Table 4. Drugs for Sexual Dysfunction Industry Restraints Table 5. Global Drugs for Sexual Dysfunction Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs for Sexual Dysfunction Revenue Share by Company (2021-2026) Table 7. Global Drugs for Sexual Dysfunction Sales Volume by Company (Units) & (2021-2026) Table 8. Global Drugs for Sexual Dysfunction Sales Volume Share by Company (2021-2026) Table 9. Global Drugs for Sexual Dysfunction Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Drugs for Sexual Dysfunction Company Ranking, (2024-2026) & (USD Million) Table 11. Global Drugs for Sexual Dysfunction Key Company Manufacturing Base & Headquarters Table 12. Global Drugs for Sexual Dysfunction Company, Product Type & Application Table 13. Global Drugs for Sexual Dysfunction Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Drugs for Sexual Dysfunction by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Vardenafil (Levitra, Staxyn) Table 18. Significant Companies of Tadalafil (Cialis) Table 19. Significant Companies of Udenafil (Zydena) Table 20. Significant Companies of Sildenafil (Viagra) Table 21. Significant Companies of Others Table 22. Global Drugs for Sexual Dysfunction Sales Volume by Type 2021 VS 2025 VS 2032 (Units) Table 23. Global Drugs for Sexual Dysfunction Sales Volume by Type (2021-2026) & (Units) Table 24. Global Drugs for Sexual Dysfunction Sales Volume by Type (2027-2032) & (Units) Table 25. Global Drugs for Sexual Dysfunction Sales Volume Share by Type (2021-2026) Table 26. Global Drugs for Sexual Dysfunction Sales Volume Share by Type (2027-2032) Table 27. Global Drugs for Sexual Dysfunction Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Drugs for Sexual Dysfunction Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Drugs for Sexual Dysfunction Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Drugs for Sexual Dysfunction Sales Value Share by Type (2021-2026) Table 31. Global Drugs for Sexual Dysfunction Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Retail Pharmacies Table 33. Significant Companies of Online Pharmacies Table 34. Significant Companies of Hospitals Table 35. Significant Companies of Clinics Table 36. Global Drugs for Sexual Dysfunction Sales Volume by Application 2021 VS 2025 VS 2032 (Units) Table 37. Global Drugs for Sexual Dysfunction Sales Volume by Application (2021-2026) & (Units) Table 38. Global Drugs for Sexual Dysfunction Sales Volume by Application (2027-2032) & (Units) Table 39. Global Drugs for Sexual Dysfunction Sales Volume Share by Application (2021-2026) Table 40. Global Drugs for Sexual Dysfunction Sales Volume Share by Application (2027-2032) Table 41. Global Drugs for Sexual Dysfunction Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Drugs for Sexual Dysfunction Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Drugs for Sexual Dysfunction Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Drugs for Sexual Dysfunction Sales Value Share by Application (2021-2026) Table 45. Global Drugs for Sexual Dysfunction Sales Value Share by Application (2027-2032) Table 46. Global Drugs for Sexual Dysfunction Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 47. Global Drugs for Sexual Dysfunction Sales by Region (2021-2026) & (Units) Table 48. Global Drugs for Sexual Dysfunction Sales Market Share by Region (2021-2026) Table 49. Global Drugs for Sexual Dysfunction Sales by Region (2027-2032) & (Units) Table 50. Global Drugs for Sexual Dysfunction Sales Market Share by Region (2027-2032) Table 51. Global Drugs for Sexual Dysfunction Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Drugs for Sexual Dysfunction Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Drugs for Sexual Dysfunction Sales Value Share by Region (2021-2026) Table 54. Global Drugs for Sexual Dysfunction Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Drugs for Sexual Dysfunction Sales Value Share by Region (2027-2032) Table 56. Global Drugs for Sexual Dysfunction Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Drugs for Sexual Dysfunction Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Drugs for Sexual Dysfunction Sales by Country: 2021 VS 2025 VS 2032 (Units) Table 59. Global Drugs for Sexual Dysfunction Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Drugs for Sexual Dysfunction Sales by Country (2021-2026) & (Units) Table 61. Global Drugs for Sexual Dysfunction Sales Market Share by Country (2021-2026) Table 62. Global Drugs for Sexual Dysfunction Sales by Country (2027-2032) & (Units) Table 63. Global Drugs for Sexual Dysfunction Sales Market Share by Country (2027-2032) Table 64. Global Drugs for Sexual Dysfunction Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Drugs for Sexual Dysfunction Sales Value Market Share by Country (2021-2026) Table 66. Global Drugs for Sexual Dysfunction Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Drugs for Sexual Dysfunction Sales Value Market Share by Country (2027-2032) Table 68. Boston Scientific Corporation Company Information Table 69. Boston Scientific Corporation Business Overview Table 70. Boston Scientific Corporation Drugs for Sexual Dysfunction Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Boston Scientific Corporation Drugs for Sexual Dysfunction Product Portfolio Table 72. Boston Scientific Corporation Recent Development Table 73. CSBio Company Information Table 74. CSBio Business Overview Table 75. CSBio Drugs for Sexual Dysfunction Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. CSBio Drugs for Sexual Dysfunction Product Portfolio Table 77. CSBio Recent Development Table 78. Dong-A ST Company Information Table 79. Dong-A ST Business Overview Table 80. Dong-A ST Drugs for Sexual Dysfunction Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Dong-A ST Drugs for Sexual Dysfunction Product Portfolio Table 82. Dong-A ST Recent Development Table 83. General Factory Company Information Table 84. General Factory Business Overview Table 85. General Factory Drugs for Sexual Dysfunction Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. General Factory Drugs for Sexual Dysfunction Product Portfolio Table 87. General Factory Recent Development Table 88. Hims Company Information Table 89. Hims Business Overview Table 90. Hims Drugs for Sexual Dysfunction Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Hims Drugs for Sexual Dysfunction Product Portfolio Table 92. Hims Recent Development Table 93. Lilly ICOS LLC Company Information Table 94. Lilly ICOS LLC Business Overview Table 95. Lilly ICOS LLC Drugs for Sexual Dysfunction Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Lilly ICOS LLC Drugs for Sexual Dysfunction Product Portfolio Table 97. Lilly ICOS LLC Recent Development Table 98. Lupin Company Information Table 99. Lupin Business Overview Table 100. Lupin Drugs for Sexual Dysfunction Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Lupin Drugs for Sexual Dysfunction Product Portfolio Table 102. Lupin Recent Development Table 103. Meda Pharmaceuticals Company Information Table 104. Meda Pharmaceuticals Business Overview Table 105. Meda Pharmaceuticals Drugs for Sexual Dysfunction Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Meda Pharmaceuticals Drugs for Sexual Dysfunction Product Portfolio Table 107. Meda Pharmaceuticals Recent Development Table 108. Menarini Group Company Information Table 109. Menarini Group Business Overview Table 110. Menarini Group Drugs for Sexual Dysfunction Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Menarini Group Drugs for Sexual Dysfunction Product Portfolio Table 112. Menarini Group Recent Development Table 113. Metuchen Pharma Company Information Table 114. Metuchen Pharma Business Overview Table 115. Metuchen Pharma Drugs for Sexual Dysfunction Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Metuchen Pharma Drugs for Sexual Dysfunction Product Portfolio Table 117. Metuchen Pharma Recent Development Table 118. SK Chemicals. Company Information Table 119. SK Chemicals. Business Overview Table 120. SK Chemicals. Drugs for Sexual Dysfunction Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. SK Chemicals. Drugs for Sexual Dysfunction Product Portfolio Table 122. SK Chemicals. Recent Development Table 123. Vivus, Inc. Company Information Table 124. Vivus, Inc. Business Overview Table 125. Vivus, Inc. Drugs for Sexual Dysfunction Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Vivus, Inc. Drugs for Sexual Dysfunction Product Portfolio Table 127. Vivus, Inc. Recent Development Table 128. Bayer AG Company Information Table 129. Bayer AG Business Overview Table 130. Bayer AG Drugs for Sexual Dysfunction Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Bayer AG Drugs for Sexual Dysfunction Product Portfolio Table 132. Bayer AG Recent Development Table 133. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Company Information Table 134. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Business Overview Table 135. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Drugs for Sexual Dysfunction Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Drugs for Sexual Dysfunction Product Portfolio Table 137. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Recent Development Table 138. Pfizer Inc Company Information Table 139. Pfizer Inc Business Overview Table 140. Pfizer Inc Drugs for Sexual Dysfunction Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Pfizer Inc Drugs for Sexual Dysfunction Product Portfolio Table 142. Pfizer Inc Recent Development Table 143. Lilly Company Information Table 144. Lilly Business Overview Table 145. Lilly Drugs for Sexual Dysfunction Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Lilly Drugs for Sexual Dysfunction Product Portfolio Table 147. Lilly Recent Development Table 148. Sanofi Company Information Table 149. Sanofi Business Overview Table 150. Sanofi Drugs for Sexual Dysfunction Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Sanofi Drugs for Sexual Dysfunction Product Portfolio Table 152. Sanofi Recent Development Table 153. Teva Pharmaceutical Industries Ltd. Company Information Table 154. Teva Pharmaceutical Industries Ltd. Business Overview Table 155. Teva Pharmaceutical Industries Ltd. Drugs for Sexual Dysfunction Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Teva Pharmaceutical Industries Ltd. Drugs for Sexual Dysfunction Product Portfolio Table 157. Teva Pharmaceutical Industries Ltd. Recent Development Table 158. Key Raw Materials Table 159. Raw Materials Key Suppliers Table 160. Drugs for Sexual Dysfunction Distributors List Table 161. Drugs for Sexual Dysfunction Customers List Table 162. Research Programs/Design for This Report Table 163. Authors List of This Report Table 164. Secondary Sources Table 165. Primary Sources List of Figures Figure 1. Drugs for Sexual Dysfunction Product Image Figure 2. Global Drugs for Sexual Dysfunction Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Sexual Dysfunction Sales Value (2021-2032) & (US$ Million) Figure 4. Global Drugs for Sexual Dysfunction Sales (2021-2032) & (Units) Figure 5. Global Drugs for Sexual Dysfunction Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Drugs for Sexual Dysfunction Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Vardenafil (Levitra, Staxyn) Image Figure 10. Tadalafil (Cialis) Image Figure 11. Udenafil (Zydena) Image Figure 12. Sildenafil (Viagra) Image Figure 13. Others Image Figure 14. Global Drugs for Sexual Dysfunction Sales Volume by Type (2021 VS 2025 VS 2032) & (Units) Figure 15. Global Drugs for Sexual Dysfunction Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Drugs for Sexual Dysfunction Sales Volume Share by Type (2021-2032) Figure 17. Global Drugs for Sexual Dysfunction Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Drugs for Sexual Dysfunction Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Drugs for Sexual Dysfunction Sales Value Share by Type (2021-2032) Figure 20. Retail Pharmacies Image Figure 21. Online Pharmacies Image Figure 22. Hospitals Image Figure 23. Clinics Image Figure 24. Global Drugs for Sexual Dysfunction Sales Volume by Application (2021 VS 2025 VS 2032) & (Units) Figure 25. Global Drugs for Sexual Dysfunction Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Drugs for Sexual Dysfunction Sales Volume Share by Application (2021-2032) Figure 27. Global Drugs for Sexual Dysfunction Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Drugs for Sexual Dysfunction Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Drugs for Sexual Dysfunction Sales Value Share by Application (2021-2032) Figure 30. Global Drugs for Sexual Dysfunction Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 31. Global Drugs for Sexual Dysfunction Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Drugs for Sexual Dysfunction Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Drugs for Sexual Dysfunction Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Drugs for Sexual Dysfunction Sales Value (2021-2032) & (US$ Million) Figure 35. North America Drugs for Sexual Dysfunction Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Drugs for Sexual Dysfunction Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Drugs for Sexual Dysfunction Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Drugs for Sexual Dysfunction Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Drugs for Sexual Dysfunction Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Drugs for Sexual Dysfunction Sales Value (2021-2032) & (US$ Million) Figure 41. South America Drugs for Sexual Dysfunction Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Drugs for Sexual Dysfunction Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Drugs for Sexual Dysfunction Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Drugs for Sexual Dysfunction Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Drugs for Sexual Dysfunction Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Vardenafil (Levitra, Staxyn)
  • Tadalafil (Cialis)
  • Udenafil (Zydena)
  • Sildenafil (Viagra)
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospitals
  • Clinics
Companies covered
  • Boston Scientific Corporation
  • CSBio
  • Dong-A ST
  • General Factory
  • Hims
  • Lilly ICOS LLC
  • Lupin
  • Meda Pharmaceuticals
  • Menarini Group
  • Metuchen Pharma
  • SK Chemicals.
  • Vivus, Inc.
  • Bayer AG
  • Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
  • Pfizer Inc
  • Lilly
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Drugs for Sexual Dysfunction Sales Value (2021-2032)
  4. 1.2.2 Global Drugs for Sexual Dysfunction Sales Volume (2021-2032)
  5. 1.2.3 Global Drugs for Sexual Dysfunction Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Drugs for Sexual Dysfunction Market Dynamics
  1. 2.1 Drugs for Sexual Dysfunction Industry Trends
  2. 2.2 Drugs for Sexual Dysfunction Industry Drivers
  3. 2.3 Drugs for Sexual Dysfunction Industry Opportunities and Challenges
  4. 2.4 Drugs for Sexual Dysfunction Industry Restraints
3 Drugs for Sexual Dysfunction Market by Company
  1. 3.1 Global Drugs for Sexual Dysfunction Company Revenue Ranking in 2025
  2. 3.2 Global Drugs for Sexual Dysfunction Revenue by Company (2021-2026)
  3. 3.3 Global Drugs for Sexual Dysfunction Sales Volume by Company (2021-2026)
  4. 3.4 Global Drugs for Sexual Dysfunction Average Price by Company (2021-2026)
  5. 3.5 Global Drugs for Sexual Dysfunction Company Ranking (2024-2026)
  6. 3.6 Global Drugs for Sexual Dysfunction Company Manufacturing Base and Headquarters
  7. 3.7 Global Drugs for Sexual Dysfunction Company Product Type and Application
  8. 3.8 Global Drugs for Sexual Dysfunction Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Drugs for Sexual Dysfunction Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Drugs for Sexual Dysfunction Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Drugs for Sexual Dysfunction Market by Type
  1. 4.1 Drugs for Sexual Dysfunction Type Introduction
  2. 4.1.1 Vardenafil (Levitra, Staxyn)
  3. 4.1.2 Tadalafil (Cialis)
  4. 4.1.3 Udenafil (Zydena)
  5. 4.1.4 Sildenafil (Viagra)
  6. 4.1.5 Others
  7. 4.2 Global Drugs for Sexual Dysfunction Sales Volume by Type
  8. 4.2.1 Global Drugs for Sexual Dysfunction Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Drugs for Sexual Dysfunction Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Drugs for Sexual Dysfunction Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Drugs for Sexual Dysfunction Sales Value by Type
  12. 4.3.1 Global Drugs for Sexual Dysfunction Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Drugs for Sexual Dysfunction Sales Value by Type (2021-2032)
  14. 4.3.3 Global Drugs for Sexual Dysfunction Sales Value Share by Type (2021-2032)
5 Drugs for Sexual Dysfunction Market by Application
  1. 5.1 Drugs for Sexual Dysfunction Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospitals
  5. 5.1.4 Clinics
  6. 5.2 Global Drugs for Sexual Dysfunction Sales Volume by Application
  7. 5.2.1 Global Drugs for Sexual Dysfunction Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Drugs for Sexual Dysfunction Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Drugs for Sexual Dysfunction Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Drugs for Sexual Dysfunction Sales Value by Application
  11. 5.3.1 Global Drugs for Sexual Dysfunction Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Drugs for Sexual Dysfunction Sales Value by Application (2021-2032)
  13. 5.3.3 Global Drugs for Sexual Dysfunction Sales Value Share by Application (2021-2032)
6 Drugs for Sexual Dysfunction Regional Sales and Value Analysis
  1. 6.1 Global Drugs for Sexual Dysfunction Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for Sexual Dysfunction Sales by Region (2021-2032)
  3. 6.2.1 Global Drugs for Sexual Dysfunction Sales by Region: 2021-2026
  4. 6.2.2 Global Drugs for Sexual Dysfunction Sales by Region (2027-2032)
  5. 6.3 Global Drugs for Sexual Dysfunction Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Drugs for Sexual Dysfunction Sales Value by Region (2021-2032)
  7. 6.4.1 Global Drugs for Sexual Dysfunction Sales Value by Region: 2021-2026
  8. 6.4.2 Global Drugs for Sexual Dysfunction Sales Value by Region (2027-2032)
  9. 6.5 Global Drugs for Sexual Dysfunction Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Drugs for Sexual Dysfunction Sales Value (2021-2032)
  12. 6.6.2 North America Drugs for Sexual Dysfunction Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Drugs for Sexual Dysfunction Sales Value (2021-2032)
  15. 6.7.2 Europe Drugs for Sexual Dysfunction Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Drugs for Sexual Dysfunction Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Drugs for Sexual Dysfunction Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Drugs for Sexual Dysfunction Sales Value (2021-2032)
  21. 6.9.2 South America Drugs for Sexual Dysfunction Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Drugs for Sexual Dysfunction Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Drugs for Sexual Dysfunction Sales Value Share by Country, 2025 VS 2032
7 Drugs for Sexual Dysfunction Country-level Sales and Value Analysis
  1. 7.1 Global Drugs for Sexual Dysfunction Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs for Sexual Dysfunction Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Drugs for Sexual Dysfunction Sales by Country (2021-2032)
  4. 7.3.1 Global Drugs for Sexual Dysfunction Sales by Country (2021-2026)
  5. 7.3.2 Global Drugs for Sexual Dysfunction Sales by Country (2027-2032)
  6. 7.4 Global Drugs for Sexual Dysfunction Sales Value by Country (2021-2032)
  7. 7.4.1 Global Drugs for Sexual Dysfunction Sales Value by Country (2021-2026)
  8. 7.4.2 Global Drugs for Sexual Dysfunction Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Drugs for Sexual Dysfunction Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Drugs for Sexual Dysfunction Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Drugs for Sexual Dysfunction Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Boston Scientific Corporation
  2. 8.1.1 Boston Scientific Corporation Company Information
  3. 8.1.2 Boston Scientific Corporation Business Overview
  4. 8.1.3 Boston Scientific Corporation Drugs for Sexual Dysfunction Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Boston Scientific Corporation Drugs for Sexual Dysfunction Product Portfolio
  6. 8.1.5 Boston Scientific Corporation Recent Developments
  7. 8.2 CSBio
  8. 8.2.1 CSBio Company Information
  9. 8.2.2 CSBio Business Overview
  10. 8.2.3 CSBio Drugs for Sexual Dysfunction Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 CSBio Drugs for Sexual Dysfunction Product Portfolio
  12. 8.2.5 CSBio Recent Developments
  13. 8.3 Dong-A ST
  14. 8.3.1 Dong-A ST Company Information
  15. 8.3.2 Dong-A ST Business Overview
  16. 8.3.3 Dong-A ST Drugs for Sexual Dysfunction Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Dong-A ST Drugs for Sexual Dysfunction Product Portfolio
  18. 8.3.5 Dong-A ST Recent Developments
  19. 8.4 General Factory
  20. 8.4.1 General Factory Company Information
  21. 8.4.2 General Factory Business Overview
  22. 8.4.3 General Factory Drugs for Sexual Dysfunction Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 General Factory Drugs for Sexual Dysfunction Product Portfolio
  24. 8.4.5 General Factory Recent Developments
  25. 8.5 Hims
  26. 8.5.1 Hims Company Information
  27. 8.5.2 Hims Business Overview
  28. 8.5.3 Hims Drugs for Sexual Dysfunction Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Hims Drugs for Sexual Dysfunction Product Portfolio
  30. 8.5.5 Hims Recent Developments
  31. 8.6 Lilly ICOS LLC
  32. 8.6.1 Lilly ICOS LLC Company Information
  33. 8.6.2 Lilly ICOS LLC Business Overview
  34. 8.6.3 Lilly ICOS LLC Drugs for Sexual Dysfunction Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Lilly ICOS LLC Drugs for Sexual Dysfunction Product Portfolio
  36. 8.6.5 Lilly ICOS LLC Recent Developments
  37. 8.7 Lupin
  38. 8.7.1 Lupin Company Information
  39. 8.7.2 Lupin Business Overview
  40. 8.7.3 Lupin Drugs for Sexual Dysfunction Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Lupin Drugs for Sexual Dysfunction Product Portfolio
  42. 8.7.5 Lupin Recent Developments
  43. 8.8 Meda Pharmaceuticals
  44. 8.8.1 Meda Pharmaceuticals Company Information
  45. 8.8.2 Meda Pharmaceuticals Business Overview
  46. 8.8.3 Meda Pharmaceuticals Drugs for Sexual Dysfunction Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Meda Pharmaceuticals Drugs for Sexual Dysfunction Product Portfolio
  48. 8.8.5 Meda Pharmaceuticals Recent Developments
  49. 8.9 Menarini Group
  50. 8.9.1 Menarini Group Company Information
  51. 8.9.2 Menarini Group Business Overview
  52. 8.9.3 Menarini Group Drugs for Sexual Dysfunction Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Menarini Group Drugs for Sexual Dysfunction Product Portfolio
  54. 8.9.5 Menarini Group Recent Developments
  55. 8.10 Metuchen Pharma
  56. 8.10.1 Metuchen Pharma Company Information
  57. 8.10.2 Metuchen Pharma Business Overview
  58. 8.10.3 Metuchen Pharma Drugs for Sexual Dysfunction Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Metuchen Pharma Drugs for Sexual Dysfunction Product Portfolio
  60. 8.10.5 Metuchen Pharma Recent Developments
  61. 8.11 SK Chemicals.
  62. 8.11.1 SK Chemicals. Company Information
  63. 8.11.2 SK Chemicals. Business Overview
  64. 8.11.3 SK Chemicals. Drugs for Sexual Dysfunction Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 SK Chemicals. Drugs for Sexual Dysfunction Product Portfolio
  66. 8.11.5 SK Chemicals. Recent Developments
  67. 8.12 Vivus, Inc.
  68. 8.12.1 Vivus, Inc. Company Information
  69. 8.12.2 Vivus, Inc. Business Overview
  70. 8.12.3 Vivus, Inc. Drugs for Sexual Dysfunction Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Vivus, Inc. Drugs for Sexual Dysfunction Product Portfolio
  72. 8.12.5 Vivus, Inc. Recent Developments
  73. 8.13 Bayer AG
  74. 8.13.1 Bayer AG Company Information
  75. 8.13.2 Bayer AG Business Overview
  76. 8.13.3 Bayer AG Drugs for Sexual Dysfunction Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Bayer AG Drugs for Sexual Dysfunction Product Portfolio
  78. 8.13.5 Bayer AG Recent Developments
  79. 8.14 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
  80. 8.14.1 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Company Information
  81. 8.14.2 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Business Overview
  82. 8.14.3 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Drugs for Sexual Dysfunction Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Drugs for Sexual Dysfunction Product Portfolio
  84. 8.14.5 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Recent Developments
  85. 8.15 Pfizer Inc
  86. 8.15.1 Pfizer Inc Company Information
  87. 8.15.2 Pfizer Inc Business Overview
  88. 8.15.3 Pfizer Inc Drugs for Sexual Dysfunction Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Pfizer Inc Drugs for Sexual Dysfunction Product Portfolio
  90. 8.15.5 Pfizer Inc Recent Developments
  91. 8.16 Lilly
  92. 8.16.1 Lilly Company Information
  93. 8.16.2 Lilly Business Overview
  94. 8.16.3 Lilly Drugs for Sexual Dysfunction Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Lilly Drugs for Sexual Dysfunction Product Portfolio
  96. 8.16.5 Lilly Recent Developments
  97. 8.17 Sanofi
  98. 8.17.1 Sanofi Company Information
  99. 8.17.2 Sanofi Business Overview
  100. 8.17.3 Sanofi Drugs for Sexual Dysfunction Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Sanofi Drugs for Sexual Dysfunction Product Portfolio
  102. 8.17.5 Sanofi Recent Developments
  103. 8.18 Teva Pharmaceutical Industries Ltd.
  104. 8.18.1 Teva Pharmaceutical Industries Ltd. Company Information
  105. 8.18.2 Teva Pharmaceutical Industries Ltd. Business Overview
  106. 8.18.3 Teva Pharmaceutical Industries Ltd. Drugs for Sexual Dysfunction Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Teva Pharmaceutical Industries Ltd. Drugs for Sexual Dysfunction Product Portfolio
  108. 8.18.5 Teva Pharmaceutical Industries Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Drugs for Sexual Dysfunction Value Chain Analysis
  2. 9.1.1 Drugs for Sexual Dysfunction Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Drugs for Sexual Dysfunction Sales Mode & Process
  6. 9.2 Drugs for Sexual Dysfunction Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Drugs for Sexual Dysfunction Distributors
  9. 9.2.3 Drugs for Sexual Dysfunction Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst